Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1984 May;51(5):523–529. doi: 10.1136/hrt.51.5.523

Hypertrophic obstructive cardiomyopathy. Effects of acute and chronic verapamil treatment on left ventricular systolic and diastolic function.

D M Anderson, G L Raff, T A Ports, B H Brundage, W W Parmley, K Chatterjee
PMCID: PMC481543  PMID: 6539120

Abstract

Changes in left ventricular systolic and diastolic function and outflow gradient were evaluated in patients with obstructive hypertrophic cardiomyopathy after intravenous acute treatment with verapamil (15 patients) and after six months of oral chronic treatment (11 patients). All patients had severe symptoms despite beta blockade, and the condition of all but two improved appreciably after chronic treatment with verapamil. Resting left ventricular outflow tract gradient decreased in six of 15 patients after intravenous verapamil, and in five of 11 patients after long term treatment, but there was no change in provocable gradients nor any correlation between changes in gradient and improvement in symptoms. Left ventricular ejection rate did not change after intravenous or oral treatment. End systolic pressure/end systolic volume index remained unchanged after oral verapamil treatment. Whereas left ventricular total stroke volume index and end diastolic volume index increased without any significant change in left ventricular end diastolic pressure, indicating improved left ventricular diastolic function. In some patients the left ventricular diastolic pressure-volume curve shifted downwards or to the right or both. These findings suggest that improvement in symptoms with verapamil in patients with obstructive hypertrophic cardiomyopathy is unlikely to be related to changes in left ventricular outflow gradient or in systolic function and may be related to improved diastolic function.

Full text

PDF
526

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bonow R. O., Rosing D. R., Bacharach S. L., Green M. V., Kent K. M., Lipson L. C., Maron B. J., Leon M. B., Epstein S. E. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation. 1981 Oct;64(4):787–796. doi: 10.1161/01.cir.64.4.787. [DOI] [PubMed] [Google Scholar]
  2. Chatterjee K., Raff G., Anderson D., Parmley W. W. Hypertrophic cardiomyopathy--therapy with slow channel inhibiting agents. Prog Cardiovasc Dis. 1982 Nov-Dec;25(3):193–210. doi: 10.1016/0033-0620(82)90016-0. [DOI] [PubMed] [Google Scholar]
  3. Edwards R. H., Kristinsson A., Warrell D. A., Goodwin J. F. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Br Heart J. 1970 Mar;32(2):219–225. doi: 10.1136/hrt.32.2.219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Epstein S. E., Rosing D. R. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation. 1981 Sep;64(3):437–441. doi: 10.1161/01.cir.64.3.437. [DOI] [PubMed] [Google Scholar]
  5. Frank M. J., Abdulla A. M., Canedo M. I., Saylors R. E. Long-term medical management of hypertrophic obstructive cardiomyopathy. Am J Cardiol. 1978 Dec;42(6):993–1001. doi: 10.1016/0002-9149(78)90687-2. [DOI] [PubMed] [Google Scholar]
  6. GRUBSCHMIDT H. A., SOKOLOW M. The reliability of high voltage of the QRS complex as a diagnostic sign of left ventricular hypertrophy in adults. Am Heart J. 1957 Nov;54(5):689–694. doi: 10.1016/0002-8703(57)90423-4. [DOI] [PubMed] [Google Scholar]
  7. HARRISON D. C., BRAUNWALD E., GLICK G., MASON D. T., CHIDSEY C. A., ROSS J., Jr EFFECTS OF BETA ADRENERGIC BLOCKADE ON THE CIRCULATION WITH PARTICULAR REFERENCE TO OBSERVATIONS IN PATIENTS WITH HYPERTROPHIC SUBAORTIC STENOSIS. Circulation. 1964 Jan;29:84–98. doi: 10.1161/01.cir.29.1.84. [DOI] [PubMed] [Google Scholar]
  8. Hanrath P., Mathey D. G., Kremer P., Sonntag F., Bleifeld W. Effect of verapamil on left ventricular isovolumic relaxation time and regional left ventricular filling in hypertrophic cardiomyopathy. Am J Cardiol. 1980 Jun;45(6):1258–1264. doi: 10.1016/0002-9149(80)90487-7. [DOI] [PubMed] [Google Scholar]
  9. Hanrath P., Schlüter M., Sonntag F., Diemert J., Bleifeld W. Influence of verapamil therapy on left ventricular performance at rest and during exercise in hypertrophic cardiomyopathy. Am J Cardiol. 1983 Sep 1;52(5):544–548. doi: 10.1016/0002-9149(83)90023-1. [DOI] [PubMed] [Google Scholar]
  10. Hubner P. J., Ziady G. M., Lane G. K., Hardarson T., Scales B., Oakley C. M., Goodwin J. F. Double-blind trial of propranolol and practolol in hypertrophic cardiomyopathy. Br Heart J. 1973 Nov;35(11):1116–1123. doi: 10.1136/hrt.35.11.1116. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Kaltenbach M., Hopf R., Kober G., Bussmann W. D., Keller M., Petersen Y. Treatment of hypertrophic obstructive cardiomyopathy with verapamil. Br Heart J. 1979 Jul;42(1):35–42. doi: 10.1136/hrt.42.1.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lorell B. H., Paulus W. J., Grossman W., Wynne J., Cohn P. F., Braunwald E. Improved diastolic function and systolic performance in hypertrophic cardiomyopathy after nifedipine. N Engl J Med. 1980 Oct 2;303(14):801–803. doi: 10.1056/NEJM198010023031407. [DOI] [PubMed] [Google Scholar]
  13. Lorell B. H., Paulus W. J., Grossman W., Wynne J., Cohn P. F. Modification of abnormal left ventricular diastolic properties by nifedipine in patients with hypertrophic cardiomyopathy. Circulation. 1982 Mar;65(3):499–507. doi: 10.1161/01.cir.65.3.499. [DOI] [PubMed] [Google Scholar]
  14. Maron B. J., Gottdiener J. S., Epstein S. E. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981 Sep;48(3):418–428. doi: 10.1016/0002-9149(81)90068-0. [DOI] [PubMed] [Google Scholar]
  15. McKenna W. J., Harris L., Perez G., Krikler D. M., Oakley C., Goodwin J. F. Arrhythmia in hypertrophic cardiomyopathy. II: Comparison of amiodarone and verapamil in treatment. Br Heart J. 1981 Aug;46(2):173–178. doi: 10.1136/hrt.46.2.173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Rosing D. R., Condit J. R., Maron B. J., Kent K. M., Leon M. B., Bonow R. O., Lipson L. C., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol. 1981 Sep;48(3):545–553. doi: 10.1016/0002-9149(81)90086-2. [DOI] [PubMed] [Google Scholar]
  17. Rosing D. R., Kent K. M., Borer J. S., Seides S. F., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. I. Hemodynamic effects. Circulation. 1979 Dec;60(6):1201–1207. doi: 10.1161/01.cir.60.6.1201. [DOI] [PubMed] [Google Scholar]
  18. Rosing D. R., Kent K. M., Maron B. J., Epstein S. E. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Circulation. 1979 Dec;60(6):1208–1213. doi: 10.1161/01.cir.60.6.1208. [DOI] [PubMed] [Google Scholar]
  19. Sagawa K., Suga H., Shoukas A. A., Bakalar K. M. End-systolic pressure/volume ratio: a new index of ventricular contractility. Am J Cardiol. 1977 Nov;40(5):748–753. doi: 10.1016/0002-9149(77)90192-8. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES